Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook

Three main pillars to unlock the potential of proprietary technology platforms and intellectual property:A proprietary non-gene editing technology...

Related Keywords

United Kingdom ,Mont Saint Guibert ,Waals Gewest ,Belgium ,London ,City Of ,Michel Lussier ,David Georges ,Exchange Commission ,Intellectual Property ,Chief Executive Officer ,Celyad Oncology ,Molecular Therapy ,Nucleic Acids ,Mol Ther Nucleic ,Private Securities Litigation Reform Act ,Annual Report ,Oncology Contacts ,Media Contact ,